摘要
目的探讨对于急性肺栓塞患者通过合用利伐沙班与低分子肝素进行治疗的临床价值。方法抽取2018年10月—2020年4月74例急性肺栓塞患者,并依据用药方案分组,对照组患者以低分子肝素钙+华法林进行治疗,同期观察组患者以低分子肝素钙+利伐沙班进行治疗,对比2组临床疗效、肺功能指标与凝血功能指标改善情况。结果观察组治疗总有效率为97.30%,对照组为78.38%,差异具有统计学意义P<0.05;2组患者治疗前PT、D-D、APTT对比中P>0.05,差异不具有统计学意义;治疗后观察组的PT、APTT高于对照组,D-D低于对照组,差异具有统计学意义P<0.05;2组患者治疗前FEV1、FEV1%pred、FVC%pred对比中P>0.05,经治疗观察组的FEV1、FEV1%pred、FVC%pred均高于对照组,差异具有统计学意义P<0.05;治疗前2组患者的PaO_(2)、PaCO_(2)比较中P>0.05,差异不具有统计学意义,治疗后观察组患者的PaO_(2)高于对照组,PaCO_(2)低于对照组,且2组患者治疗后的PaO_(2)、PaCO_(2)比较中P<0.05差异具有统计学意义;观察组患者的药物不良反应率为8.11%,对照组为10.81%,P>0.05,差异不具有统计学意义。结论对于急性肺栓塞患者合用利伐沙班与低分子肝素治疗可取得满意疗效,且有助于改善凝血与肺通气功能。
Objective To explore the clinical value of combined treatment with rivaroxaban and low molecular weight heparin for patients with acute pulmonary embolism.Methods From October 2018 to April 2020,74 patients with acute pulmonary embolism in our hospital were selected and grouped according to the medication plan.The control group was treated with low molecular weight heparin calcium+warfarin,and the observation group was treated with low molecular heparin during the same period.Calcium+rivaroxaban was used for treatment,and the clinical efficacy,lung function index and blood coagulation function index improvement of the two groups were compared.Results The total effective rate was 97.30%in the observation group and 78.38%in the control group(P<0.05);There was no significant difference in Pt,D-D and APTT between the two groups before treatment(P>0.05);After treatment,Pt and APTT in the observation group were higher than those in the control group,and D-D was lower than that in the control group(P<0.05);Before treatment,FEV1,FEV1%PRED and FVC%PRED in the two groups were significantly higher than those in the control group(P<0.05);Before treatment,there was no significant difference in PaO_(2) and PaCO_(2) between the two groups(P>0.05).After treatment,PaO_(2) in the observation group was higher than that in the control group,PaCO_(2) was lower than that in the control group,and there was significant difference in PaO_(2) and PaCO_(2) between the two groups(P<0.05);The adverse drug reaction rate was 8.11%in the observation group and 10.81%in the control group(P>0.05),The difference was not statistically significant.Conclusion For patients with acute pulmonary embolism,the combined treatment of rivaroxaban and low-molecular-weight heparin can achieve satisfactory results and help to improve blood coagulation and pulmonary ventilation.
作者
刘红梅
杨海升
LIU Hongmei;YANG Haisheng(Department of Respiratory and Critical Care Medicine,Wuhai People’s Hospital,Wuhai Inner Mongolia 016000,China)
出处
《中国继续医学教育》
2021年第28期162-166,共5页
China Continuing Medical Education
关键词
急性肺栓塞
利伐沙班
低分子肝素
凝血功能
肺通气功能
疗效
acute pulmonary embolism
rivaroxaban
low molecular weight heparin
coagulation function
lung ventilation function
